Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4693-4699

  Lohri, Corinne ^a   Hutzli Schaltegger, Claudia S ^b   Van Den Broek, Maries ^c   Wenger, Roland H ^c   Ruegg, Curzio ^d   Fink, Daniel ^e   Fehr, Mathias K ^f   Knuth, Alexander ^g   Zweifel, Martin ^h  

^a Spital of Buelach   (Switzerland)

^b Department of Anesthesia and Intensive Care Medicine Regional Hospital Maennedorf   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d University of Fribourg   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Kantonsspital Frauenfeld   (Switzerland)

^g HAMAD MEDICAL CORPORATION   (Qatar)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemokine receptor 1; Intercellular adhesion molecule 1; Neutrophilic granulocyte; Tumor angiogenesis; Vascular endothelial growth factor receptor 1

Indexed keywords

CARBOPLATIN; CHEMOKINE RECEPTOR CXCR1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOMA; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; BREAST TUMOR; CHEMOKINE RECEPTOR 1; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR ANGIOGENESIS;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CHEMOKINE RECEPTOR 1; INTERCELLULAR ADHESION MOLECULE 1; NEUTROPHILIC GRANULOCYTE; TUMOR ANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INTERCELLULAR ADHESION MOLECULE-1; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; RECEPTORS, INTERLEUKIN-8A; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84908675938     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Frei E and Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69: 585-594, 1980.
2. Elghetany MT, Ge Y, Patel J, Martinez J and Uhrova H: Flow cytometric study of neutrophilic granulopoiesis in normal bone marrow using an expanded panel of antibodies: Correlation with morphologic assessments. J Clin Lab Anal 18: 36-41, 2004.
3. Anderson DC and Springer TA: Leukocyte adhesion deficiency: an inherited defect in the MAC-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 38: 175-194, 1987.
4. Buckley CD, Ross EA, McGettrick HM, Osborne CE, Haworth O, Schmutz C, Stone PC, Salmon M, Matharu NM, Vohra RK, Nash GB and Rainger GE: Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. J Leukoc Biol 79: 303-311, 2006.
5. Krysiak O, Bretschneider A, Zhong E, Webb J, Hopp H, Verlohren S, Fuhr N, Lanowska M, Nonnenmacher A, Vetter R, Jankowski J, Paul M and Schonfelder G: Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with pre-eclampsia from additional migration by VEGF. Circ Res 97: 1253-1261, 2005.
6. Ancelin M, Chollet-Martin S, Herve MA, Legrand C, El Benna J and Perrot-Applanat M: Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 84: 502-512, 2004.
7. Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, M VDB, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH and Zweifel M: Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1. Anticancer Res 31: 3115-3124, 2011.
8. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A and Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor FLT1. Blood 87: 3336-3343, 1996.
9. Elghetany MT and Davis BH: Impact of preanalytical variables on granulocytic surface antigen expression: A review. Cytometry Part B: Clin Cytom 65B: 1-5, 2005.
10. Payne CM, Glasser L, Tischler ME, Wyckoff D, Cromey D, Fiederlein R and Bohnert O: Programmed cell death of the normal human neutrophil: An in vitro model of senescence. Microsc Res Tech 28: 327-344, 1994.
11. Kotz KT, Xiao W, Miller-Graziano C, Qian W-J, Russom A, Warner EA, Moldawer LL, De A, Bankey PE, Petritis BO, Camp DG, Rosenbach AE, Goverman J, Fagan SP, Brownstein BH, Irimia D, Xu W, Wilhelmy J, Mindrinos MN, Smith RD, Davis RW, Tompkins RG and Toner M: Clinical microfluidics for neutrophil genomics and proteomics. Nat Med 16: 1042-1047, 2010.
12. Lu Y-Z, Wu C-C, Huang Y-C, Huang C-Y, Yang C-Y, Lee T-C, Chen C-F and Yu LC-H: Neutrophil priming by hypoxic preconditioning protects against epithelial barrier damage and enteric bacterial translocation in intestinal ischemia/reperfusion. Lab Invest 92: 783-796, 2012.
13. Borregaard N and Cowland JB: Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503-3521, 1997.
14. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ and Ellis LM: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24: 2647-2653, 2005.
15. + cells. Eur J Haematol 70: 143-150, 2003.
16. De Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, Ribatti D, Walls AF and Marone G: Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 177: 7322-7331, 2006.
17. Selheim F, Holmsen H and Vassbotn FS: Identification of functional VEGF receptors on human platelets. FEBS Lett 512: 107-110, 2002.
18. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H and Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (FLT) closely related to the FMS family. Oncogene 5: 519-524, 1990.
19. Heydarian M, McCaffrey T, Florea L, Yang Z, Ross MM, Zhou W and Maynard SE: Novel splice variants of sFLT1 are upregulated in pre-eclampsia. Placenta 30: 250-255, 2009.
20. Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
21. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S and Keshet E: A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and pre-eclampsia. Circ Res 102: 1566-1574, 2008.
22. Thomas CP, Andrews JI and Liu KZ: Intronic polyadenylation signal sequences and alternate splicing generate human soluble FLT1 variants and regulate the abundance of soluble FLT1 in the placenta. FASEB J 21: 3885-3895, 2007.
23. Cai J, Jiang WG, Grant MB and Boulton M: Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281: 3604-3613, 2006.
24. Rahimi N, Golde TE and Meyer RD: Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR1/FLT1 in leukemic cancer cells. Cancer Res 69: 2607-2614, 2009.
25. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA and Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95: 8795-8800, 1998.
26. Meyer RD, Mohammadi M and Rahimi N: A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR1/FLT1. J Biol Chem 281: 867-875, 2006.